IL1B and chronic kidney disease: Moreover, suppression of IL-1 signaling provides cardiovascular benefits in CKD patients who are otherwise at increased risk of cardiovascular events (CVE) due to systemic inflammation and vascular problems associated with CKD progression (94, 95).